AlphaQuest LLC Has $712,000 Stock Position in Dynavax Technologies Corporation $DVAX

Key Points

• AlphaQuest LLC significantly increased its stake in Dynavax Technologies by 134.3%, acquiring an additional 31,483 shares, bringing its total holdings to 54,920 shares valued at approximately $712,000.
• Dynavax Technologies recently saw analyst upgrades, with reports from Wall Street Zen raising its rating from "hold" to "buy" and a price target set at $32.00 by JMP Securities.
• The company's quarterly earnings exceeded expectations, reporting $95.44 million in revenue and $0.14 EPS, which is higher than the consensus estimate of $0.12.

AlphaQuest LLC lifted its holdings in shares of Dynavax Technologies Corporation (NASDAQ:DVAX - Free Report) by 134.3% during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 54,920 shares of the biopharmaceutical company's stock after purchasing an additional 31,483 shares during the quarter. AlphaQuest LLC's holdings in Dynavax Technologies were worth $712,000 as of its most recent filing with the SEC.

Other hedge funds have also made changes to their positions in the company. Russell Investments Group Ltd. raised its holdings in Dynavax Technologies by 96.5% in the fourth quarter. Russell Investments Group Ltd. now owns 2,381 shares of the biopharmaceutical company's stock valued at $30,000 after acquiring an additional 1,169 shares in the last quarter. DekaBank Deutsche Girozentrale purchased a new position in Dynavax Technologies in the 1st quarter valued at $30,000. Caitong International Asset Management Co. Ltd grew its position in Dynavax Technologies by 5,485.7% in the 1st quarter. Caitong International Asset Management Co. Ltd now owns 2,346 shares of the biopharmaceutical company's stock valued at $30,000 after buying an additional 2,304 shares during the last quarter. GF Fund Management CO. LTD. purchased a new position in Dynavax Technologies in the 4th quarter valued at $35,000. Finally, GAMMA Investing LLC boosted its position in shares of Dynavax Technologies by 88.4% during the 1st quarter. GAMMA Investing LLC now owns 7,729 shares of the biopharmaceutical company's stock worth $100,000 after purchasing an additional 3,627 shares in the last quarter. Institutional investors and hedge funds own 96.96% of the company's stock.

Analyst Ratings Changes

Several equities research analysts have commented on DVAX shares. Wall Street Zen upgraded shares of Dynavax Technologies from a "hold" rating to a "buy" rating in a research report on Saturday, August 9th. JMP Securities reaffirmed a "market outperform" rating and set a $32.00 price target on shares of Dynavax Technologies in a research note on Friday, August 22nd. Three investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $24.33.

Dynavax Technologies Price Performance

DVAX stock traded down $0.15 during trading on Friday, hitting $10.12. The stock had a trading volume of 1,164,789 shares, compared to its average volume of 1,879,064. The company's 50 day moving average price is $10.62 and its two-hundred day moving average price is $11.30. Dynavax Technologies Corporation has a 1-year low of $9.22 and a 1-year high of $14.63. The stock has a market cap of $1.19 billion, a price-to-earnings ratio of -22.00 and a beta of 1.09. The company has a debt-to-equity ratio of 0.45, a quick ratio of 6.01 and a current ratio of 6.65.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $0.14 EPS for the quarter, beating the consensus estimate of $0.12 by $0.02. Dynavax Technologies had a positive return on equity of 5.10% and a negative net margin of 16.67%.The company had revenue of $95.44 million during the quarter, compared to analysts' expectations of $87.55 million. On average, sell-side analysts forecast that Dynavax Technologies Corporation will post 0.32 EPS for the current fiscal year.

Insider Activity at Dynavax Technologies

In other Dynavax Technologies news, Director Scott Dunseth Myers bought 3,800 shares of Dynavax Technologies stock in a transaction dated Friday, August 22nd. The stock was bought at an average cost of $10.82 per share, for a total transaction of $41,116.00. Following the purchase, the director owned 35,004 shares in the company, valued at $378,743.28. This represents a 12.18% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Company insiders own 2.98% of the company's stock.

Dynavax Technologies Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.